

Index

Notes: Page numbers in *italics* refer to figures; page numbers in **bold** refer to tables

A

abdominal aorta
aneurysm see aortic aneurysm (abdominal aorta)
 anterior branches 311–312, 312
 atherosclerotic occlusions 317–318, 318
dissection see aortic dissection
intramural hematoma see aortic intramural hematoma (IMH)
 lateral branches 311, 312
 long intraluminal thrombosis 315–316
 normal MR angiography 311–312, 312
 posterior branches 311, 312
 thrombosis 313, 317, 318
 wall inflammation (aortitis) 316, 316–317
 wall thickening 315, 315–316
 abdominal arteries
normal MR angiography 311–312, 312
 pathologic conditions, MRA 313–321
 abdominal belt 219
 abdominal lymph nodes *see intra-abdominal lymph nodes*
 abdominal trauma
kidneys 151, 152
liver, children 348
spleen 102, 350
 abdominal vascular malformations 350–351
see also under MR angiography (MRA)
 abdominal veins
normal MR angiography 312
 pathologic entities, MRA 325–328, 350–351
abscess see individual types of abscess
 ACTH, ectopic secretion 185
 Addison disease 184
 adenoma
adrenal see adrenal adenoma
colon 119, 131–132
hepatocellular 11, 14, 18, 346
renal 155, 161
 adenomyoma 261
 adenomyosis, uterus 258, 260, 260–261
 adnexa 285–299
normal anatomy 287
see also ovaries; uterine tubes
 adrenal adenoma 181, 185, 186
 aldosterone-producing 185, 186

atypical, inhomogeneous images 186, 188
 children 360
 functioning 185, 186
 lipid-containing 182, 186, 187, 193
 malignant tumors *vs* 186
 nonfunctioning 184, 186, 187, 188
 SI_{rel} cut-off values 183
 adrenal glands 181–194
 abscess 185
 aim of MRI 193
angiomyolipoma/myelolipoma 188, 189
 benign conditions 184–189
 benign *vs* malignant lesions 183, 184, 186, 193
 central liquefaction 185
 cortex, destruction 184
 cysts 186, 186
ganglioneuroma in children 359
hemangioma 188, 190
hemorrhage 356, 357
hyperplasia 185, 185
 indications for MRI 181
 inflammatory conditions 184–185, 193
lipid-containing tumors see adrenal adenoma
malignant tumor 184, 189–193
carcinoma see adrenocortical carcinoma, primary
children 358–360, 359
lymphoma 190
metastases 181, 190, 191
neuroblastoma see neuroblastoma
pheochromocytoma 190, 192, 192, 193, 359–360
 masses 181, 184
characterization, flowchart 193–194, 194
MRI imaging technique 181–184
contrast media 182, 184
image analysis 182–184
index of signal intensities (SI) 183
in-phase/opposed-phase imaging 181, 181, 182, 183, 193
pulse sequences 181–182, 182
normal MRI appearance 183, 184
pathologic entities, MRI appearance 184–193
children/infants 356, 358–360
sizes in children/adults 356
tuberculosis 184–185
adrenal incidentaloma 181, 184
adrenocortical adenoma see adrenal adenoma
 adrenocortical carcinoma, primary 189–190, 191
children 360
adrenocortical hyperplasia/hypersecretion 185, 185
adrenocortical insufficiency 184
ampullary cancer 77, 77
anal canal 127–141, 128, 129
indications for MRI 127
MRI imaging technique 127–128
normal MRI appearance 128–129, 129, 130, 131
pathologic conditions, MRI 136
see also rectum
anal cancer 120, 127, 136, 137
anal cushions (corpora cavernosa recti) 129
anal sphincters 128–129, 130, 131
androgen, excess production 185
aneurysm
abdominal aorta see aortic aneurysm (abdominal aorta)
inflammatory (aortic) 317, 317
renal arteries 322
visceral arteries 319
angiography, MR see MR angiography (MRA)
angioma, renal 356
angiomatosis, systemic cystic 96
angiomyolipoma
adrenal 189
hepatic, children 347
renal 160, 160, 161
children 356
angiosarcoma
renal 171
spleen 100
anocutaneous line 128
anorectal abnormalities, children/infants 342–343
anorectal abscess, MRI pulse sequences/parameters 129
anorectal angle 140
anorectal fistula
children/infants 342, 343, 345
MRI pulse sequences/parameters 129
anorectal flexure 128, 129
anorectal line 128
antispasmodic agents
gastrointestinal MRI 110
intra-abdominal lymph node MRI 332, 333
liver MRI 8
pancreas MRI 69
pelvic MRI 241, 285
rectal/anal canal MRI 127

anus
 atresia 342
 ectopic 343, 344
 imperforate 342
aortic aneurysm (abdominal aorta)
 313, 313–314
 causes 313
 contrast-enhanced 3D MRA
 313–314
 fusiform 313
 inflammatory 317, 317
 infrarenal 310, 313, 313
 multislice spiral CT 305, 313–314
 saccular 313
 treatment follow-up by 3D MRA
 314, 314
 true aneurysm 313
aortic dissection 317, 318
 chronic 316
 contrast-enhanced 3D MRA 317
 false and true lumen 316, 317
aortic intramural hematoma (IMH)
 314–316, 315
 acute/subacute 315, 315
 aortic wall thickening vs 315–316
 MR angiography 315, 315
aortic occlusion 317–318, 318
aortic stenosis 317–318, 318
aortic thrombosis 313, 317, 318
aortitis 316, 316–317
aortocaval fistula 314
appendicitis 123, 125, 125
 MRI indication 109, **109**
appendicoliths 123
arteriovenous fistula, MR angiography
 323
artifacts on MRI imaging
 arms causing wraparound 143
 motion see breathing motion artifacts; motion artifact(s)
ascites 72
 cirrhosis with 39, 41
 endometrial carcinoma 265
 ovarian cancer recurrence 298
 rectouterine pouch 248
atherosclerosis
 aortic occlusions 317–318, 318
 aortic wall thickening 315
 penetrating ulcer 314
 superior mesenteric artery 320
autoimmune hemolysis 36, 105
autosomal dominant polycystic kidney disease (ADPKD) 155, 154–156
autosplenectomy 103
azygos vein, blood flow 325

B

Bartholin cysts 274
basal cell nevus syndrome 343
benign prostatic hyperplasia (BPH)
 225, 225
 MR spectroscopy 223
 prostate cancer with 225, 226
bile ducts 47–64
 anatomic variants 56
 inflammatory conditions 55
MRCP see MRCP
 normal anatomy, MRI 51, 52, 52–53,
 55
pathologic entities, MRI 53–63
 children 348

small, normal 55
strictures/stenoses 53, 55, 55
biliary-enteric anastomosis 48
bladder (urinary) 209–217
 benign tumors 211
 carcinoma 211–214, 230
 lymph node metastases 336, 340
 papillary 213
 recurrence 212, 214, 215
 seminal vesicle involvement 212,
 214, 215
 T1 to T4 stages 212, 213, 214
 TNM staging 212, **212**, 212, 214
cervical cancer invasion 268, 269,
 272, 273
 recurrence after surgery 278, 281
congenital anomalies 210
diverticula 210, 211
hemangioma 211
hyperintense, motion artifacts 263
indications for MRI 209
inflammation 211
inhomogeneous signal intensity
 (layering) 210, 213
leiomyoma 211
lymphoma 215
malignant tumors 210, 211–215
 carcinoma see bladder, carcinoma
 rare 214–215
 recurrent 210, 212, 214, 215
 rhabdomyosarcoma (children)
 362, 363
MRI imaging technique 209–210
 contrast media 210, 212
 imaging planes 209
 pulse sequences and protocol
 209, **210**
MRI vs CT 212, 214
normal MRI appearance 129, 210
optimal filling, before MRI 209, 241,
 285
pathologic entities, MRI appearance
 210–216
 children 361–362
pheochromocytoma 211
prostate cancer invasion 231
sarcoma 215
wall, cancer invasion 212, 213, 231
blood, T1 relaxation time, MRA 306
blood flow, velocity, calculation 306
blood pool agents 307
blood transfusions, repeated, iron
 overload 348, 348
blueberry juice, as contrast medium
 49, 69
bone marrow, neuroblastoma metastases 359
bowel cleansing 109, 110, 140
bowel obstruction 342
breast cancer, metastases 20, 20, 336,
 337
breath-holding techniques
 colorectal cancer MRI 121
 intra-abdominal lymph node MRI
 332, 333
kidney and upper urinary tract MRI
 143
liver MRI 1, 2, 3, 7, 31
MRCP 48, 49
pancreas MRI 65, 66
retroperitoneum MRI 196, **196**
splenic MRI 87

see also VIBE sequence (volume-interpolated breath-hold examination)

breathing motion artifacts
gastrointestinal tract MRI 111
 intra-abdominal lymph node MRI
 333
liver MRI 3, 5–6
minimization 1, 3, 7, 31, 49, 219
pelvic MRI 241, 243, 285
see also breath-holding techniques
broad ligament, normal anatomy 287
bronze diabetes 72
Budd-Chiari syndrome (BCS) 42, 42,
 324, 351
Buscopan 110
butylscopolamine 110, 111, 112, 121,
 127

C

CA 19–9 80
calcification, tumors 19, 257, 358
Candida abscess, liver 25
cannula, indwelling 1
carcinoïd tumors 113
cardinal ligaments (Mackenrodt ligaments) 246, 246
Caroli syndrome 53, 348
Castleman disease 363
catecholamines, secretion by neuroblastoma 358
cavernous transformation, portal vein 350
CD 117 (c-kit proto-oncogene) 113,
 197
celiac trunk 311
 stenosis 319
cerebral MRI 347, 359
ceruloplasmin, deficiency 36
cervical canal 245–246
 in uterus didelphys 253, 254
cervical carcinoma 267–273
 contrast-enhanced images 267, 268
 extent, ligaments in evaluation 246,
 246
 incidence 267
 metastatic lymph nodes 267, 273,
 273
 MRI appearance 267–273
 parametrial invasion 271, 271, 272
 pulse sequences/protocol 267, **267**
 radiotherapy, MRI after 277, 279
 recurrence after surgery 278, 280,
 281
 residual tumor after radiotherapy
 278, 279
stage IA and IB 268, 270, 271
stage IIA and IIB 268, 271, 271, 272
stage IIIA and IIIB 269, 272, 272
stage IV and IVA 269, 272, 273
staging 267–273, **270**
 MRI role, vs CT 273, **273**
vaginal invasion 271, 272, 273, 275
viable vs necrotic areas 267–268,
 269
cervical intraepithelial neoplasia 267
cervix, uterine
 carcinoma *see* cervical carcinoma
 cysts 262, 262
 endometrial carcinoma invasion
 266

- cervix, uterine
fibrosis, postoperative 278, 280
mucus 249
normal anatomy 245, 245
normal MRI appearance 248, 248, 250, 251
stenosis 261, 277
T2 w images 248, 248, 250
zonal anatomy 249, 250
- chemical shift imaging (CSI) 182, 210, 292
3D MRS see MR spectroscopy, 3D
- children, abdominal MRI 341–365
abdominal vascular malformations 350–351
adrenal gland disease 356, 358–360, 359
neuroblastoma 358, 358–359, 359, 359
contraindications for MRI 342
ganglioneuroblastoma 359
ganglioneuroma 359, 360
gastrointestinal tract 342–345
hepatobiliary system 345–348, 346, 347, 348
indications for MRI 341
kidneys 352–356, 357
MRI imaging technique 341–342
coils and pulse sequences 341
contrast media 342
positioning 341
sedation 341–342
- pancreatic abnormalities 348–349
pathologic entities, MRI appearance 342–364
pelvic conditions/MRI 361–363, 363
retroperitoneum 352
splenic abnormalities 350
systemic neoplastic disease 363
chloral hydrate 341, 342
cholangiocarcinoma 11, 22, 25, 63
cholangiocellular carcinoma (Klatskin tumor) 63, 64
- cholangitis
acute 76
primary sclerosing (PSC) 61, 63
secondary sclerosing 61
- choledochal cysts 348, 349
choledochal stent 51, 53
choledocholithiasis 58
- choline, MR spectroscopy of prostate 222, 223, 223
prostate cancer 232, 233
- chordoma, presacral 362
- choriocarcinoma 261
- chromaffinoma, of adrenal gland 190, 192, 192, 193
- cirrhosis 38–42
advanced 40–42
ascites with 39, 41
confluence fibrosis, with 39, 40
contrast media use 32–33, 323
dysplastic nodules 40, 41
first MRI signs 38
indication for MRI 34
macronodular 39, 41
neoplastic lesions 39–40, 41
portal vein thrombosis 40
primary biliary 55
primary hemochromatosis and 36
regenerative lesions 40, 41, 42
siderotic nodules 39
- splenic infarction with 104
splenomegaly with 104, 105
Wilson disease 347
- citrate, MR spectroscopy of prostate 222, 222, 223, 233
prostate cancer 232, 233
- c-kit proto-oncogene 113, 197
- clear cell tumor, renal 356
- coils
body, pelvic MRI 243
conventional, in MR angiography 309
- endorectal
contra-indications (acute prostatitis) 224
pelvic MRI (female) 242
prostate MRI 219, 219, 235
rectum MRI 128
- flexible wraparound for neonates/
infants 341
- phased-array
bladder MRI 209
intra-abdominal lymph nodes 332
kidney and urinary tract 143–144
liver MRI 2
MR angiography 306, 309
MRCP 47
pelvic MRI 242, 243, 285
rectum and anal canal MRI 127–128
retroperitoneum MRI 195
spleen MRI 87
- surface, bile/pancreatic duct MRI 47
- colon 119–125
adenoma 119, 131–132
ascending, carcinoma 122
carcinoma see colorectal cancer
Crohn disease 121, 123
diverticulitis 121, 123, 124, 124
inflammatory disease 121, 123–125
lymphatic drainage 120
MRI vs CT 124, 125
polyp 120
radiation-induced changes 121, 123
sigmoid 122, 123, 124
ulcerative colitis 121, 123, 123
see also gastrointestinal tract
- colonography, MR see MR colonography (MRC)
- colorectal cancer 119–121, 131–132
“apple core” appearance 119, 119
distant metastases 121
liver metastases 19, 19–20, 28–29, 121
local recurrence 121
MRI role, and vs PET/CT 121, 125
screening, MR colonography 109
spread 119–120
TNM staging 119, 119, 132
see also rectal cancer
- common bile duct
diameter after cholecystectomy 55, 63
normal MRCP 51, 52, 54
stones 55, 58–59, 63
- common channel syndrome 348
- common hepatic duct, bifurcation, cholangiocarcinoma 63
- computed tomography (CT)
intramural hematoma of aorta 315
- MRI comparison *see individual conditions*
- spiral and multislice (SCT/MSCT) 305
aortic aneurysm 305, 313–314
aortic dissection 317
pancreas 65
renal trauma 151
- congenital anomalies/diseases
bladder (urinary) 210
gastrointestinal tract 342–343
kidney 150, 150, 352, 352
pancreas 71–72
prostate 223
uterus *see under* uterus
vagina 274
- congenital mesoblastic nephroma 355–356
- contra-indications for MRI 241, 342
- contrast media
administration methods 9, 10
low rate of adverse effects 306
nonspecific *see* gadolinium-based contrast media
tissue-specific *see* iron oxide particles; superparamagnetic iron oxide particles (SPIO)
see also specific anatomic regions (e.g. liver)
- copper
intratumoral, hepatocellular carcinoma 21
toxicity, Wilson disease 42–43, 347
- corpus luteum cysts 289
- creatine, MR spectroscopy of prostate 222, 223, 223
prostate cancer 232, 233
- Crohn disease 109
antrum 112
children 343, 345
colon 121, 123
complications 116, 124
enterocutaneous fistula 117
perianal fistulas 136, 137, 137, 138
rectum 136–138, 137, 138
small intestine 114–115, 116
ulcerative colitis vs 123
- Crohn Disease Activity Index (CDAI) 114–115
- cryptorchidism 361
- CT during arterial portography (CTAP) 33
- Curarino triad 363
- Cushing syndrome 185
- cyst(s) *see individual cysts*
- cystadenocarcinoma
ovarian 295, 297, 361
pancreatic 79
- cystadenofibroma, serous 294
- cystadenoma
mucinous 79, 81, 290, 291, 295
ovarian 290, 291, 295, 295
pancreatic 77, 79, 79, 81
serous 77, 79, 79, 290
- cystic duct
MRCP 55
stones 58
- cystic fibrosis, pancreas 71
- cystic pancreatic neoplasms 77, 79, 79
- cystitis 211
- cystoscopy, bladder cancer 214

D

defecation disorders 125, 140
Denonvilliers fascia 221
dermoid cysts 292–293
diazepam 341
diffusion-weighted imaging (DWI),
 rectal/anal canal imaging 128
dilatation and curettage, MRI after
 276
diverticula
 duodenal 115
 urinary bladder 210, 211
diverticulitis, colon 121, 123, 124, 124
diverticulosis 123
Dotarem (Gd-DOTA) 8–9, 34, 127, 306
DOTATOC 125
doughnut sign, liver metastases 19
duct-penetrating sign 55, 80, 84
duodenal C-loop 70
duodenal diverticula 115
duodenum, pancreatic head differentiation (MRI) 69, 70
dynamic contrast-enhanced MRI *see*
 contrast media
dysgerminoma 297–298, 361
dystocia 301

E

echinococcal infection 186, 346, 346
echo-planar imaging (EPI), liver 5
ectocervix 249, 250
ectopic pregnancy 288
edema
 intrahepatic 37, 38
 pancreatitis in children 348
 peritumoral (retroperitoneal
 tumors) 200
ejaculatory ducts 221, 221
embryonal carcinoma 361
endocervical glands 249
endocervix, endometrial carcinoma
 invasion 266
endodermal sinus tumors 361, 362
endometrial carcinoma 262–266
 epidemiology and risk factors 262
 MRI appearance 263–266
 myometrial invasion 262, 263, 264,
 266
 pulse sequence/protocol 263, **263**
 recurrence after surgery 278, 280
 residual tumor after radiotherapy
 278, 280
 stage I and IA 263, 263, 266
 stage IB/IC 263, 264, 266
 stage II, III and IV 265, 266
 staging/FIGO classification
 263–266, **266**
 errors and overstaging 266
 MRI role 266–267
 T2 w images (high intensity) 263
 vaginal spread 262
endometrial cavity 253
 blood clot in 247, 248
endometrioma (endometriotic cysts)
 290, 292, 292
endometriosis 253, 254, 290
 adenomyosis *vs* 258
endometriotic cyst 290, 292, 292
endometrium 247
 abnormal thickening 264

menstrual cycle effects 247, 247,
 248
polyps 261, 261
 radiotherapy effect 276–277, 277
Endorem 8, 27
endoscopic retrograde cholangiopan-
 creatography (ERCP) 47
enterocutaneous fistula 117
Eovist, 3D MR angiography 307
esophageal squamous cell carcinoma,
 metastases 112
esophageal varices 323

F

fallopian tubes *see* uterine tubes
fast spin echo sequence *see* FSE se-
 quence
fat saturation techniques 66
 spectral/effective, liver imaging 7, 8,
 35
fat suppression
 adrenal gland imaging 181, 183
 for children/infants 341
 liver imaging 2, 3, 4, 7–8, 9, 35
 pancreas imaging 66
 pelvic MRI 242–243
 retroperitoneum imaging 196, **196**
 small intestinal MRI 115
 splenic imaging 87
 see also short tau inversion recovery
 (STIR) sequence
fecal incontinence 343
female genitalia
 anomalies 360–361
 disease/tumors in children 361, 362
 see also specific anatomic structures
fetopelvic disproportion 301
fibroids *see* uterus, leiomyoma
 (fibroids)
fibromuscular dysplasia 319, 320
fibrosarcoma
 renal 171
 retroperitoneal 203, 204
FIGO classification
 cervical carcinoma 268, **270**
 endometrial carcinoma 263, 266,
 266
FLASH 144, 196
flow compensation (gradient moment
 nulling), liver imaging 7
flow-related signal enhancement, MR
 angiography 305–306
flow-related signal loss (phase shifts)
 305, 306
focal nodular hyperplasia (FNH), liver
 see under liver
follicular cysts 287–288, 289
Fourier space (k-space) 307
FSE sequence
 for children/infants 341
 liver MRI 3, 5
 pelvic MRI 242, 252
 retroperitoneum MRI 196
fungal infections 25, 102, 185

G

gadobutrol *see* Gadovist (gadobutrol)
gadofosveset (Vasovist) 307
gadolinium-based contrast media
 3D MR angiography 306–307

adrenal gland imaging 182, 184
bladder imaging 210
children/infants MRI 342
intr-abdominal lymph nodes 333,
 334, 336
kidney and upper urinary tract 146,
 148, 174
liver imaging 8, 9, 27, 29, 31–32, 34,
 91
pancreas imaging 66, 68
prostate imaging 220, 238
rectal imaging 127
retroperitoneum imaging 196
splenic imaging 87, 91
uterine zonal anatomy 247, 248
gadolinium chelates 306, 307
gadolinium-DTPA 306, 307
gadolinium ions (Gd^{3+}) 306
Gadovist (gadobutrol) 8–9, 306, 307
gallbladder
 adenomyomatosis 55, 62
 disorders in children 348
 polyps 55, 61
 stones 55, 58, 60
Gamma-Gandy bodies 39, 105, 106
ganglioneuroblastoma 359
ganglioneuroma 359, 360
Gartner duct, cysts 274, 275
gastric cancer *see* stomach, ade-
 carcinoma
gastric leiomyoma 112
gastric leiomyosarcoma 112
gastric lymphoma 112
gastric vein, left, dilatation 323, 323
gastrinoma 22, 80, 82
gastrointestinal stromal tumor (GIST)
 113–114, 115, 197
gastrointestinal tract 109–126
 advantages of MRI, over CT 109, 121,
 125
 congenital anomalies 342–343
 functional/dynamic MRI 125
 inadequate distention and tumor
 mimic 111
 indications for MRI 109, **109**
 motion artifacts and prevention 110
MRI imaging technique 109–112
 abdominal imaging 110–111
 contrast media 110, 111–112, 125
 patient preparation 109–110
 pelvic imaging 111
 pulse sequences 110–111
pathologic conditions, MRI appear-
 ance 112–125
 children/infants 342–345
PET/CT vs MRI 121, 125
 see also colon; small intestine;
 stomach
Gaucher disease, spleen 102
genitalia, anomalies 360–361
germ cell tumors, testicular 361
gestational trophoblastic disease
 (GTD) 261
ghosting/ghosts, liver imaging 6
giant cell aortitis 316
glucagon, rectal/anal canal imaging
 127
glucagonoma 80
Gorlin syndrome 343
graafian follicles 287
gradient echo sequences *see* GRE
 sequences

gradient moment nulling (flow compensation), liver 7
 gradient moment rephrasing (GMR) 306
 graft rejection, renal 175, 177
 granuloma, hepatic 43, 345
 granulosa cell tumors 293, 361
 GRE sequences
 3D
 adrenal gland 182, 182
 gastrointestinal tract 110–111
 intra-abdominal lymph nodes 336
 kidney and upper urinary tract 144
 liver lesions 3, 5
 MR angiography using 307
 pancreas 66
 retroperitoneum 196
 see also VIBE sequence (volume-interpolated breath-hold examination)
 adnexa imaging 286
 intra-abdominal lymph nodes 332, 332, 333
 MR pelvimetry 301, 303, 303
 pelvic MRI 243
 portal venous MRI 323
 in pregnancy 301
 retroperitoneum imaging 196

H

hamartoma
 liver, children 345
 splenic 96
 HASTE, imaging of
 adnexa 286
 adrenal glands 181, 182, 183
 bile/pancreatic duct 48, 49, 50
 gastrointestinal tract 109, 110–111, 111, 115
 colorectal cancer 120, 121, 122
 inflammatory disease 124
 kidney and upper urinary tract 144, 146
 liver 3, 5, 5
 rectal/anal canal 128
 retroperitoneum 196, 196
 splenic 89
 hemangioendotheliomatosis, children 345
 hemangioma
 adrenal 188, 190
 bladder 211
 capillary, splenic 93
 cavernous, splenic 93
 liver 12, 13, 13–14, 15
 centripetal enhancement 30, 31
 children 345, 346
 cysts vs 12, 13, 13
 dynamic contrast-enhanced MRI 13, 14, 15, 32
 iron oxide particle injection 27, 29
 metastases vs 13, 30, 31
 retroperitoneal 200
 spleen 93, 95, 95–96
 hemangiomatosis
 liver, children 345, 346
 splenic 93, 95, 96
 hematocolpos 274, 274

hematoma
 acute adrenal 356, 358
 hepatic 22
 intramural, aortic see aortic intramural hematoma (IMH)
 perirenal 151, 152
 renal see kidney, hematoma
 splenic 102
 hematometra 278, 278
 hematometrocolpos 253
 hematosalpinx 278, 278, 290, 361, 361
 hemochromatosis
 pancreatic MRI imaging 66
 primary (hereditary)
 children 348
 liver 36, 37, 106, 348
 pancreas 71, 71–72
 spleen 105, 106
 secondary 36, 37, 72, 348
 hemoglobinuria, paroxysmal nocturnal 36, 105, 105
 hemorrhage
 adrenal 356, 357
 after biopsy for prostate cancer 227, 227, 228
 intratumoral, liver metastases 19, 21, 22
 uterine leiomyoma 258, 257
 hemorrhagic lesions, liver 22
 hemosiderin 292, 348
 hemospermia 224–225
 hepatic arteries
 MR angiography, protocol 308
 right, aberrant 319
 stenosis, and thrombosis 324
 hepatic duct, right
 aberrant 53
 normal MRCP 51
 hepatic steatosis 26, 26, 27
 hepatic veins, MR angiography 324
 hepatic venous outflow obstruction 42, 42, 324
 children 351
 hepatitis, acute 37, 38
 hepatobiliary contrast media 27, 30, 30
 hepatobiliary system, children/infants 345–348
 hepatoblastoma 346
 hepatocellular adenoma 14, 18, 346
 hepatocellular carcinoma (HCC) 11, 21–22, 23, 24
 children/infants 346–347, 347
 contrast media use 32–33
 focal, in adenomatous hyperplasia 42
 focal lesion in cirrhosis 39–40, 41
 hepatocellular adenoma vs 14
 metastases vs 27, 34
 pseudocapsule 21, 22, 23, 24
 hepatocellular nodules 39, 40–41
 hepatocytes, iron uptake 36
 hepatopathy, congestive 351
 hermaphroditism 360
 Hodgkin lymphoma
 lymph node metastases 331, 336, 338
 spleen involvement/MRI 90, 99
 see also lymphoma
 hormone therapy, prostate cancer 232–233

human chorionic gonadotropin (β-hCG) 261
 hydatidiform mole 261
 hydrometrocolpos 361
 hydronephrosis, vascular origin 356, 356
 hyperaldosteronism, primary 185, 186
 hypercortisolism 185
 hypospadias 360

ileus 110
 iliac arteries, left external, stenosis 322
 iliac crest imaging 196
 imatinib 113–114, 197
 implants, cardiac 342
 infants see children, abdominal MRI
 inferior mesenteric artery 305, 312
 inferior mesenteric vein 312, 312
 inferior phrenic arteries 311
 inferior vena cava 312
 anomalies, MRA 325–326
 compression 326
 obstruction, renal cell carcinoma 326, 326
 occlusion 42, 42
 renal tumor invasion 166, 326, 327
 inflammatory bowel disease
 children 343, 345
 MRI criteria for assessment 117, 343
 see also colon; Crohn disease; rectum; ulcerative colitis
 inflammatory ovarian disease 361
 inflammatory pseudotumor
 bowel obstruction, children 342, 344
 splenic 96, 98, 99
 in-phase (IP) imaging
 adrenal glands 181, 181, 182, 183, 193
 liver 3, 5, 6, 6, 7, 12
 insulinoma 80, 349–350
 internal iliac artery, normal MRA 312
 intersphincteric fistula 138
 intestinal duplication 342
 intra-abdominal lymph nodes
 331–340
 asymmetry, in metastases 336
 benign vs malignant enlargement 331, 336
 conglomerate 336, 337
 contrast media 333–334, 336, 338
 non-specific (gadolinium-based) 333, 334, 336
 oral 333
 tissue-specific 334
 indications for MRI 331–332, 332
 malignancy criteria 334, 336
 metastases 331, 335, 336
 melanotic 336, 337, 338
 MRI advantages over CT 331
 MRI appearance of abnormal nodes 336, 337, 338, 339
 MRI imaging technique 332–334
 imaging planes 332, 332
 pulse sequences 332, 332–333, 333
 MRI sensitivity 331, 334, 338, 339
 multiple enlarged, in malignancy 336, 337

normal MRI appearance 334, 334, 335, 339
 pelvic *see* pelvic lymph nodes
 size 331, 334
 malignancy diagnosis 334, 335, 336
 spherical transformation 336
 T1 w hyperintensity in melanoma 336, 337, 338
 T1 w hypointensity and T2 w hyperintensity 334, 334, 336
 upper abdomen, pulse sequences 332, 332, 333
 intracervical mucus 249
 intraductal papillary mucinous tumor (IPMT) 77, 79
 intrahepatic block 351
 intramural hematoma (IMH) of aorta *see* aortic intramural hematoma (IMH)
 intraperitoneal abscess, children 350
 intrathoracic lymph nodes 336
 intrauterine device (IUD) 241
 iodine-based X-ray contrast media 8–9
 iron
chelation therapy 348
deposition/storage 36, 102, 105, 106
 liver 35–36, 106
 pancreas 71, 71–72
 splenic 102, 103–104, 104, 105
 iron gluconate 286
 iron overload
 liver 35–36, 348, 348
 pancreas 71, 71–72
 iron oxide particles
bile/pancreatic ducts contrast 48, 48–49, 51
pancreas imaging 69
see also superparamagnetic iron oxide particles (SPIO)
 iron storage disease 35–36, 71, 71–72
 ischiorectal abscess 138, 139
 islet cell tumors 80, 82, 83
 liver metastases 28–29

K

kidney 143–179
advantages of MRI 143
artifacts (wraparound) 143
atrophy 151, 154
benign conditions 150–161
congenital anomalies 150, 150, 352, 352
cysts *see* renal cysts
duplex 352, 352
ectopic 150
functional imaging 174
hematoma 151, 152
 in graft recipient 175, 176
horseshoe 150, 150
indications for MRI 143
inflammation/abscess 151, 152
living donor evaluation 174, 174
lymphoma 171, 172, 173
metastases in 171, 172, 173
 MRI imaging technique 143–148
children/infants 352
coils 143–144
contrast-enhanced imaging 144, 147

contrast media 148, 174, 352, 353
precontrast imaging 144, 146
protocol for graft recipients 175
pulse sequences 144, 144, 145
for specific indications 144, 144
 MRI vs CT 143
 normal MRI appearance 146, 148
pathologic entities, MRI appearance 150–177
children 352–356
polycystic disease 154, 155–156, 352
stones 154, 154
trauma 151, 152
tumors *see* renal tumors
vascular anatomy 174, 174
see also entries beginning renal
 Kinsbourne syndrome 359
 Klatskin tumor 63, 64
 Klippel-Trenaunay-Weber syndrome 93
 Krukenberg tumor 112, 297, 297
k-space (Fourier space) 307
Kupffer cells 8, 42

L

labor, protracted 301
lactate dehydrogenase (LDH), elevated 358
Larmor frequency 306, 307
left common iliac veins 327
leiomyoma
 bladder 211
 gastric 112
 small intestine 113
uterine *see* uterus, leiomyoma (fibroids)
leiomyosarcoma
epithelioid, myxoid/granular cell types 203
 gastric 112
 prostate 237, 238
 renal 171
retroperitoneal 197, 202–203
leiosarcoma, small intestine 113
Leriche syndrome 317
leukemia, MRI of children 363
levator ani muscle 128–129, 130
lipoma
 presacral 362
retroperitoneal 202, 202
small intestine 119, 119
liposarcoma
perirenal fatty tissue 160
renal 160, 171
retroperitoneal 200, 201, 202
littoral cell angioma 96, 97
liver 1–45
abscess 25, 26, 345
adenoma 11, 14, 18, 346
adenomatous hyperplasia, focal HCC in 42
advantages/benefits of MRI 1
atrophy 25, 38, 39
 in cirrhosis 38, 39, 41
benign focal lesions 12–18
benign tumors 1, 12, 34
children/infants 345–346
see also hemangioma, liver biopsy, children 347
caudate lobe hypertrophy 43

cirrhosis *see* cirrhosis
contrast-enhanced MRI 27–30
diffuse liver disease 34, 39
focal lesion characterization 34
focal lesion diagnosis 30–33, 31, 32, 33
hepatobiliary contrast media 8, 9, 27, 28–29, 30, 30
late postcontrast images 31–32
nonspecific contrast media 31–32
SPIO (iron oxide particles) 8–9, 27, 28, 29, 30
contrast inflow, temporal course 10, 10
cysts 12, 12, 13, 91
children 345, 346, 346
diffuse disease 34–43, 35
acute infections/inflammatory 37, 38
vascular 42, 42
edema (intrahepatic) 37, 38
eggshell calcification 12
fatty infiltration 3, 6
diffuse/generalized 35, 36
focal lesions 26, 26, 27
fibrosis 38–42
confluent, cirrhosis with 39, 40
see also cirrhosis
focal lesions 1–34
benign 12–18
characterization 34
detection (contrast media use) 30–33, 31, 32, 33
fatty 26, 26, 27
hemorrhagic 22
malignant 19–22
role of MRI 30–34
focal nodular hyperplasia (FNH) 11, 14, 16, 27
dynamic MRI 30, 33
pedunculated 14, 17
granuloma 43, 345
hemangioma *see* hemangioma, liver
hilum, enlarged lymph nodes 43
incidentally detected lesions, MRI for 1
indeterminate lesions, MRI techniques 2
indications for MRI 1, 2, 34
intrapancreatic hemorrhage 42
iron deposition 35–36, 106
malignant tumors 11, 12, 27
children 346–347
see also hepatocellular carcinoma (HCC)
metastases 1, 2, 7, 11, 19–21
 from breast cancer 20, 20, 101
calcification 19
children 347
 from colorectal cancer 19, 19–20, 28–29, 121, 125
dynamic contrast-enhanced MRI 12, 19, 27, 31
fatty lesions resembling 26, 27
from gastrinoma 22
HCC vs 27, 34
hemangioma vs 13, 30, 31
hemorrhage in 19, 21, 22
hypervascular 12, 20, 21, 32
hypovascular 19, 19, 19–20, 30, 31
from islet cell carcinoma 28–29

- liver
 metastases
 melanotic (melanoma) 12, 20–21, 22, 101–102
 neuroblastoma 358, 359
 nonspecific contrast media 31–32, 91
 from pancreatic carcinoma 77, 78
 from rectal cancer 31, 132
 from renal cell carcinoma 20, 21
 tissue-specific contrast media 27, 28–29, 30, 31
 MRI technique *see liver, MRI technique*
 nodule-in-nodule 42
 nodules *see hepatocellular nodules*
 normal MRI appearance 11, 11
 parasitic infections 37
 pathology, MRI appearance
 diffuse liver disease 35–43
 focal lesions 11–26
 sarcoidosis 43
 siderotic nodules 39, 40–41
 transplantation 324, 324–325, 325
 trauma, children 348
 vascular disease 42, 42
 Wilson disease 42–43
- liver, MRI technique 1–11, **2, 5**
 coils 2
 contrast media 1, 8–9
 administration methods 9
 nonspecific (gadolinium) 8, 9, 27, 29, 31–32, 34
 tissue-specific *see below*
 fat suppression 2, 3, 4, 7, 35
 imaging planes 1–2
 motion artifacts and reduction of 5–8
see also motion artifact(s)
 patient positioning/preparation 1
 protocols 9–11
 dynamic 9–10, 10, 13, 14, 15, 34
 multiphasic 10
 static using tissue-specific contrast media 10–11
 unenhanced 9
 pulse sequences 2–8, 4, 5
 3D GRE sequence 2–3, 5
 in-phase and opposed-phase 3, 5, **6, 6, 7, 12**
 intermediate field strength T1 w 3
 T1 w imaging 2–3, 5, 6, 7, 11, **12**
 T2 w imaging 3, 5, 5, 7, 12, **12**
 turbo/fast SE (TSE, FSE) 3, 5
 tissue-specific contrast media 8–9, 10–11, 31
 hepatobiliary (low-molecular-weight) 8, 9, 27, 30, 30, 37
 SPIO (iron oxide particles) 8–9, 27, 28, 29, 30, 34, 39
 lumbar arteries 311
 lumbar lymph nodes 334
 Lumirem 342
 lung metastases 121, 132
 lymphadenopathy, retroperitoneal 326
 lymphangioma
 abdominal, children 343
 splenic 96
 lymph-hemangiomatosis 350, 351
 lymph nodes
- hilum of liver 43
 intra-abdominal *see intra-abdominal lymph nodes*
 pelvic *see pelvic lymph nodes*
 perirectal, metastases 133
 sizes, normal vs metastases 334, 335, 336
 lymphoma
 adrenal 190
 bladder 215
 children, MRI 350, 363
 gastric 112
 mesenteric 113
 ovarian 298, 298
 renal 171, 172, 173
 small intestine 113, 119, 119
 spleen involvement 90, 99, 99, 100
see also Hodgkin lymphoma; non-Hodgkin lymphoma
 lymphoproliferative disease 356
 benign atypical 363
- M**
- Mackenrodt ligaments (cardinal ligaments) 246, 246
 magnetic resonance cholangiopancreatography (MRCP) *see MRCP*
 magnetic resonance elastography (MRE) 34, 38
 magnetites *see superparamagnetic iron oxide particles (SPIO)*
 Magnevist (Gd-DTPA) 34, 66, 68, 127, 306
 male genitalia, anomalies 361
 malignant fibrous histiocytoma (MFH) 204, 205
 maximum intensity projection (MIP), MRA 308, 322
 Mayer–Rokitansky–Küster–Hauser syndrome 253, 360
 Meigs syndrome 293
 melanoma, malignant
 amelanotic, metastases 336
 liver metastases 12, 20–21, 22
 lymph node metastases 336, 337, 338
 splenic metastases 100, 101
 Ménétier disease 112
 meningocele 362, 363
 menstrual cycle
 endometrium thickness 247, 247, 248
 ovarian changes 288
 vaginal changes 249
 mesenchymal tumors 197
 granulosa cell 361
 hemangioma of liver 13, 13–14
 hepatic sarcoma 347
 retroperitoneal *see retroperitoneal soft-tissue tumors*
 mesenteric ischemia 319, 319, 320
 mesenteric lymphoma 113
 mesorectal fascia 128, 131
 mesorectum 130, 132
 metastases *see specific cancers and anatomic structures*
 methemoglobin 292
 MIBG scintigraphy, pheochromocytoma 192
 microabscesses, splenic 102
 middle sacral artery 311
 middle suprarenal arteries 311
 milk, whole, as contrast agent 342
 mononuclear phagocytic system (MPS), magnetite uptake 8, 27
 motion artifact(s) 3, 5–8
 bowel movement 3, 5–6, 49, 110, 219, 241
 causes 3, 5–6
 ghosting/ghosts 6
 minimization 6–8, 9
 gastrointestinal MRI 110, 111
 pancreatic MRI 66
 prostate MRI 219
 respiratory triggering 8, 9, 28–29
see also breath-holding techniques; fat suppression; presaturation band
 pelvic MRI 241
 pulsation artifacts 3, 6, 7
 respiratory *see breathing motion artifacts*
 urinary bladder, endometrial carcinoma MRI 263
 MP-RAGE (magnetization-prepared rapid acquisition gradient echo) 323, 336
 MR angiography (MRA) 305–330
 contrast-enhanced 3D 305, 306–310
 automatic injectors and rates 307
 coils 309
 contrast media 306–307
 k-space and timing 307
 parallel imaging techniques 308
 patient examination 309, **309–310**
 postprocessing techniques 308, 308, 310, 311, 322
 protocol **309–310**
 pulse sequences 307–308, **308**
 flow-related signal enhancement (inflow effects) 305–306
 flow-related signal loss (phase shifts) 305, 306
 imaging technique 305–310
 indications 305
 kidney and upper urinary tract 143, 144, 147, 147
 liver transplantation evaluation 324, 324, 325
 normal anatomy, appearance 311–312, 312
 pancreas 66, 83
 pathologic entities, MRI appearance 313–328
 children/infants 341, 350, 351, 351
 pelvic inflammatory disease 288
 phase-contrast (PC) 306
 renal transplantation evaluation 321, 322, 323
 time-of-flight (TOF) 305–306, 327, **327**
 unenhanced 305–306
see also individual arteries/veins
 MR colonography (MRC) 109, **109**
 colorectal cancer 120, 121, 122
 inflammatory disease of colon 123–125
 water enema or air insufflation 110
 MRCP 47–64, 65
 advantages and cost-benefits 47
 children 348, 349

indications for 47
maximum intensity projection (MIP) algorithm 48, 49, 52
normal 51, 52, 55
oral contrast media 48–49
negative (iron oxide) 48, 48–49, 51
in pancreas MRI protocol 66
patient preparation 48–49
recommended protocol 49, 50, 51, 51, 52
technique 47–51
 coils 47
 pulse sequences 48, 49, 50
MR defecography 140, 140
MR enteroclysis 109, 109, 110
MR hysterosalpingography 288, 289
MR pelvimetry 301–304
 advantages and indications 301
 imaging technique and findings 303
pelvic measures 302, 302–303
postpartum 301, 302, 302–303
prenatal 301, 303
pulse sequences 303, 303
 reference values 303
MR spectroscopy, 3D 222–223
 free induction decay (FID) signal 223
frequency spectrum 222, 223
prostate *see prostate; prostate cancer*
MR urography (MRU) 143, 144, 147, 148
 3D MR angiography with 305
renal graft recipients 175
T1 w excretory, and T2 w static 148, 149
mucoviscidosis (cystic fibrosis) 71
müllerian duct, anomalies 252–255, 360
 agenesis 360
 cysts 223
 incomplete/absent (unicornuate uterus) 252, 254, 254
 partial nonfusion 252, 254, 254
multicystic renal dysplasia 352, 353
Multihance (Gd-BOPTA) 8, 9, 31, 306, 307
multilocular cystic nephroma 160
multiplanar reconstruction (MPR) 308, 322
multiple endocrine neoplasia type 1 (MEN 1) 80
multiple endocrine neoplasia type 2A/2B 192
myelolipoma, adrenal 188, 189
myometrium
 invasion by endometrial carcinoma 262, 263, 264, 266
 invasion by endometrial tissue (adenomyosis) 258, 260, 260–261
 normal MRI appearance 247, 247, 248

N
Nabothian cysts 246, 249, 262, 262
navigator echo technique 8, 9, 48
neonates and infants, MRI imaging 92, 341
 see also children, abdominal MRI

nephroblastoma *see Wilms tumor (nephroblastoma)*
nephroblastomatosis 355, 355
nephrogenic systemic fibrosis (NSF) 148
nephroma
 congenital mesoblastic 355–356
 multilocular cystic 160, 356
neuroblastoma 192–193, 358, 358–359, 359
 staging 359
neuroendocrine tumors 79, 80, 125
neurofibroma, and neurofibromatosis 204, 205
neurovascular bundle, prostate base
 see prostate
Niemann–Pick disease 102
non-Hodgkin lymphoma
 adrenal 190
 inflammatory bowel disease vs 345
 lymph node metastases 331, 336
 mesenteric 113
 ovarian 298, 298
 spleen involvement/MRI 99, 99, 100
 see also lymphoma

O

omentum, endometrial carcinoma invasion 265
Omniscan 8–9, 66, 68, 306
oncocytoma 155, 158, 159
opposed-phase (OP) imaging
 adrenal glands 181, 181, 182, 183, 193
 liver 3, 5, 6, 7
opsoclonus 359
Optimark (gadoversetamide) 8–9
oral contraceptives 14, 248, 249
Ormond disease (retroperitoneal fibrosis) 204, 206
ovarian cancer 285, 294–295
 borderline 295, 296, 298
 criteria of malignancy 295, 296, 297
 FIGO/UICC stages 297
 histologic classes 294–295
 lymph node metastases 331
 recurrence 298, 298
 serous papillary 296
 staging laparotomy 295
ovarian fibroma 293, 294
 malignant transformation 293, 294, 295
 uterine leiomyoma vs 256
ovarian follicles 287–288, 288
ovarian fossae 287
ovarian ligament 245, 287
ovarian teratomas 361, 362
ovarian veins 287, 326–328
2D TOF MRA 327, 327
thrombosis, septic puerperal 328
ovaries 285–299
 benign tumors 289–293
 cystic 289–293, 361, 362
 benign vs malignant masses 286, 295
 blood supply and venous drainage 287
 cortex, and medulla 287, 288
 cystadenoma 290, 291, 295, 295
 dermoid cysts 292–293, 293
 endometriotic cysts 290, 292, 292

fibroma *see ovarian fibroma*
follicular cysts 287–288, 289
functional cysts 289, 290, 361
functioning tumors 293, 294
hemorrhagic cysts 289, 290
indications for MRI 285
inflammatory disease in children 361
lymphatic drainage 287
lymphoma 298, 298
malignant tumors 294–296
 children 361
 metastases 295, 297
 primary *see ovarian cancer*
menstrual cycle effects 288
MRI imaging technique 285–286
 contrast media 286
 imaging planes 285
 pulse sequences/protocol 285–286, 286
normal anatomy 287
normal MRI appearance 287, 287–288
pathologic entities, MRI appearance 288–298, 361
polycystic ovary syndrome 289–290, 361, 362
torsion 289, 292, 361
zonal anatomy 287, 288

P

pacemakers 342
PACE technique, bile/pancreatic duct imaging 48
pancreas 65–86
 anatomy 65, 65, 70
 annular 66, 71
 atrophy 74
 calcification 74, 76
 chronic 75
 congenital anomalies/diseases 71–72
 see also pancreas divisum
 cystadenoma, children 350
 cystic fibrosis 71
 cysts 71
 endocrine/exocrine secretions 49, 65
 outflow obstruction 52
 fibrosis 74
 focal enlargement 80
 functions 65
 head 69, 70, 70
 carcinoma 76, 76–77
 enlargement 71, 72, 75
 pseudocyst 73
 indications for MRI 65, 66
 inflammatory disease *see pancreatitis*
 lipomatosis 70, 70
 lymphatic drainage 65, 70, 77
 mass(es) 57, 61, 63
 MRI imaging technique 66–69, 67
 contrast media 66, 68–69
 dynamic 66, 68, 69, 83
 imaging planes 66
 pulse sequences 66, 67, 68, 69
MRI vs CT 65, 72, 74, 77
neoplasms 76–80
 ampullary cancer 77, 77

- pancreas
neoplasms
 carcinoma *see* pancreatic carcinoma
 children 349–350
 cystic 77, 79, **79**
 islet cell tumors 28–29, 80, 82, 83
 pseudotumors *vs* 80, 83, 84
normal MRI 70
normal parenchyma 68, 69, 70
pathologic conditions, MRI appearance 71–83
 children/infants 348–349
primary hemochromatosis 71, 71–72
pseudocysts *see* pancreatic pseudocysts
pseudotumors, *vs* neoplasms 80, 83, 84
string of pearls appearance 73, 74
transplant 83
- pancreas divisum 52–53, 54, 58, 71
MRI indication **66**
- pancreatic carcinoma 76–77
absence of duct-penetrating sign 83
benign lesions *vs* 65
children 350
classification **77**
head of pancreas 76, 76–77
metastases and spread 77, 78
MRI indication **66**
neuroendocrine 21, 79, 80
portal vein invasion 324
signal intensity 77, 78
tail of pancreas 76, 78
vascular encasement 77, 83
- pancreatic duct 47–64
accessory 52, 71
anatomic variants 52–53, 55, 56, 71
carcinoma 76
dilatation 73, 75, 77
gradual narrowing *vs* abrupt obstruction 83
inflammatory conditions 55
MRCP protocol 49, **50**, 51, 51, 65
 see also MRCP
normal anatomy, MRI 51, 52, 52–53, 55
normal MRCP 51, 52
pathologic entities, MRI appearance 53–63
small, normal 55
stones 55, 56, 58–59, 74
 children 348, 349
strictures/stenoses 53, 55, 55
 children 349
 vs malignancy 55
- pancreatic pseudocysts 55, 64, 72, 73, 74, 75–76
children 348
hemorrhagic 74
- pancreatitis **66**, 72–76
acute 54, 56, 72, 74
 complications 72, 73, 74
 edematous 72, 72
children 348, 349
chronic 52, 55, 65, 70, 73, 74–75
recurrent 48, 80, 348, 349
- papilla of Vater 52, 55
- papillary sclerosis 57
- para-anal horseshoe abscess 139
- paracolpium (paravaginal tissues) 248, 249, 251
- paraesophageal varices 323
- paraganglioma 192
- parallel imaging 2, 128, 143
- paramagnetic low-molecular-weight compounds 8, 9, 68
 3D MR angiography 306, 307
- parametrium 246, 270
 cervical cancer involvement 271, 271, 272
 normal MRI appearance 249, 251
- parapelvic cysts 154, 156
- parasitic cysts, adrenal 186
- parasitic infections, liver 37
- paraumbilical veins 324
- paravaginal tissues 248, 249, 251
- parovarian cyst 290, 290
- paroxysmal nocturnal hemoglobinuria 36, 105, 105
- pelvic abscess 345, 345
- pelvic arteries
 normal MRA 311–312, 312
 pathologic conditions, MRA 313–321, 318
- pelvic floor, functional disorders 140
- pelvic inflammatory disease (PID) 288, 289
- pelvic inlet, measures 302, 302–303
- pelvic lymph nodes
 contrast media for MRI 333, 334
 metastatic, MRI appearance 336
 MRI pulse sequences 128, **332**, 332–333, 333
 normal 334, 334, 335
 size for malignancy diagnosis 336
- pelvic MRI (female) 241–244, 285–286
artifacts 241
congenital uterine anomalies 252–253, **253**
contraindications 241
contrast media 244
imaging planes 242, 285
imaging strategy/protocol 242, 244, **244**
menstrual status 285
patient preparation/position 241, 285
pulse sequences 242, 285
 adnexa imaging 285–286, **286**
 congenital anomalies 253, **253**
 uterus and vagina imaging 242–243, **244**
- pelvic outlet, measures 302, 303
- pelvic veins
 2D TOF MRA 327, **327**
 normal MRA 312
 pathologic entities, MRA 326–328
 thrombosis 326–328, 327
- pelvimetry 301–304
 MR *see* MR pelvimetry
- penetrating atherosclerotic ulcer (PAU) 314
- Pepper syndrome 359
- perfluoroctyl bromide, as contrast agent 342
- perfusion-weighted imaging (PWI), rectal/anal canal imaging 128
- perianal abscess 136, 137–138
- perianal fistula 127, 128, 136, 137, **137**
- peripancreatic fluid 70, 72, 75
- perirectal abscess 127
- perirectal fat 131, 132, 133, 135
- perirectal lymph nodes, metastases 132, 133
- perirectal hematoma 151, 152
- peristalsis, motion artifact 3, 5–6, 49, 110, 219, 241
- peritoneal carcinosis, gelatinous 121
- peritoneal cyst 298
- peritoneum, covering uterus 246, 246
- phase contrast (PC), MR angiography 306
- phased-array coils *see* coils, phased-array
- phase-encoding gradient 307
- phase-ordering technique (ROPE) 8, 9
- phase shifts, MR angiography 305, 306
- pheochromocytoma 190, 192, 192, 193
- bladder 211
 children 359–360
- polycystic kidney disease 154, 155–156, 352
- polycystic ovary syndrome 289–290, 361, 362
- polyethylene glycol electrolyte solution (PEG-ES) 109, 110, 343
- polyps
 colon 120
 endometrium 261, 261
 gallbladder 55, 61
- porphyria cutanea tarda 36
- portal hypertension 34, 184, 323, 324
 children 360
 MR angiography 321, 323–324
 retroperitoneal collaterals 324, 324
- portal veins
 invasion by pancreatic tumor 324
 normal MRA 312, 312
 pathological MRA 308, 312, 312, 321, 323–324
 children 350–351
 stagnant blood in 350
 stenosis 324
 thrombosis 40, 91, 350–351
- portal venous system
 contrast-enhanced 3D MRA 323, 323
- normal MRA 312, 312
pathologic entities, MRA 321–325
 intraluminal dephasing phenomena 323
- portosystemic collaterals, MRA 321, 323–324
- portosystemic shunts 325
- positron emission tomography (PET), MRI *vs*, colorectal cancer 121
- posthepatic block *see* hepatic venous outflow
- postmenopausal bleeding 262
- postmenopausal women
 ovaries 288
 uterus 248, 249, 277
 vagina 249
- pregnancy 261, 301
 ectopic 288
 MRI during first trimester 301
- MR pelvimetry *see* MR pelvimetry
- ovarian veins 326
- prehepatic block 350

presacral teratoma 362–363, 364
presacral tumors, children 362–363, 363
presaturation band 241, 242, 243
 liver imaging 6–7
 pancreas imaging 66
presaturation pulses 242, 242, 243
PRESS (point-resolved spectroscopy) 222
primary biliary cirrhosis (PBC) 55
primary sclerosing cholangitis (PSC) 61, 63
Primovist (Gd-EOB-DTPA) 8, 9, 31, 31, 33
Prohance (gadoteridol) 8–9
prostate 219–240
 abscess 224
 anatomy 220–221, 221
 benign hyperplasia *see* benign prostatic hyperplasia (BPH)
 cancer *see* prostate cancer (*below*)
 congenital anomalies 223
 cysts 223, 224
 indications for MRI 219
 inflammatory conditions 224–225
 malignant tumors 226–238, 237
 adenocarcinoma *see* prostate cancer
 atypical carcinomas 236, 237
 mucinous carcinoma 236–237
 rhabdomyosarcoma 362
 sarcoma 237, 237–238, 238
 transitional cell carcinoma 237
MRI imaging technique 219–220
 contrast media 220, 238
 dynamic imaging 220
 endorectal coil 219, 221, 235
 imaging planes 219–220
 pulse sequences and protocol 220, 220
MRI/MR spectroscopy combined 222, 232, 233
MR spectroscopy (3D) 222, 222–223, 223
 citrate, choline and creatine 222–223, 232, 233
neovascular bundle at base 221, 221, 222
 cancer involvement 228, 229
nodules 225, 225
normal MRI appearance 129, 220–223
pathologic entities, MRI appearance 223–238
pseudocapsule 225, 225
scar formation 224
sensitivity of MRI 219
T1 w image homogeneity 221
T2 w images 221, 226, 235, 238
zonal subdivision 221, 221, 226
 transitional zone 221, 221, 223, 225
prostate cancer 226–235, 235, 236
 accuracy of MRI 230
 benign prostatic hyperplasia with 225, 226
 biopsy 226
 hemorrhage after 227, 227, 228
 MR-guided 234, 234
 capsular penetration criteria 227–228, 228

dynamic contrast-enhanced 230, 232, 232
endorectal coil MR imaging 226–232
extent assessment 227–228, 232
extracapsular 227–228, 228, 229
lymph node involvement 235, 236, 336
MRI/MR spectroscopy combined 232, 233, 234
MRI vs CT or ultrasound 235
MR spectroscopy 232–234, 233
neovascularization 226
peripheral/transitional zone 226, 227
radiologist's experience importance 230, 232
radiotherapy, MR spectroscopy after 233, 235
recurrent 219, 235, 235, 236
routes of spread 228, 229, 230
seminal vesicle invasion 228, 229, 230, 230
small solitary tumors 228
stage T1 and T2 226
stage T2A 222
stage T3 and T3 b 226, 229, 230
stage T4 226, 228, 230, 231
staging/TNM classification 219, 226, 226
prostatectomy, prostate cancer recurrence after 235, 235, 236
prostate-specific antigen (PSA) 219, 230, 233, 235
prostatic capsule 222, 227
prostatic utricle 360
prostatitis 224
proton density (PD) sequence 90, 332, 341
proton motion 305
pseudocapsule
 hepatocellular carcinoma 21, 22, 23, 24
 prostate 225, 225
 soft-tissue sarcoma 200
 uterine leiomyoma 256, 257, 260
 Wilms tumor 353, 354–355
pseudocysts
 adrenal 186
 pancreatic *see* pancreatic pseudocysts
 splenic 93, 102
pseudodiverticula, urinary bladder 210
pseudomyxoma peritonei 121
pubic symphysis, normal MRI appearance 129
pubococcygeal line 140
pulmonary sequester 351
pyosalpinx 288

R

radiation cystitis 211
radiation enteritis 115, 121, 123
radiation-induced hepatitis 37
radiotherapy
 cervical carcinoma 277, 278, 279, 280
 prostate cancer 233, 235
uterus MRI appearance after 276–277, 277, 280
vaginal MRI appearance after 277, 277–278
readout gradient 307
rectal ampulla 128
rectal cancer 131, 132
 circumferential resection margin 132
 distant metastasis 132
 lymph node metastases 132, 133
 MRI pulse sequences/parameters 129, 132
 MRI role/appearance 132–133, 133, 134
 recurrence 121, 135, 135–136
 spread 120–121, 127
 staging 132, 132
 T1, T2 and T3 132, 133
 T4 133, 134
 total mesorectal excision 128, 132
 see also colorectal cancer
rectocele 140, 140
rectouterine pouch (pouch of Douglas) 248, 287, 288, 298
rectum 127–141
 anatomy 128–129, 129, 130
 anterior displacement, children 343
 blood supply 129
 cervical cancer invasion 272, 273, 278, 281
 Crohn disease 136–138, 137, 138
 functional disorders 140
 indications for MRI 127
 inflammatory bowel disease 127, 128, 136–138
 lymphatic drainage 120, 132
 MRI imaging technique 127–128
 MRI vs CT 127
 normal, MRI appearance 128–131, 129, 130
 pathologic entities, MRI appearance 131–140
 pelvic (rectal ampulla) 128
 perineal *see* anal canal
 venous drainage 132
 wall, layers 129, 130, 131
relaxation enhancement (RARE) technique, MRCP 48
renal adenoma 155, 161
renal angiosarcoma 171
renal arteries
 aneurysm 322
 contrast-enhanced MRA 311, 320, 320–321
 evaluation in living kidney donors 320, 321, 322
 evaluation in transplant recipients 321, 322, 323
 normal MR angiography 311
 occlusion, children 356, 356
 PTA and stenting 320–321
 stenosis 320, 320, 321, 323
 children 356, 357
 variants 320, 321, 322
renal cell carcinoma (RCC) 161–163, 162
 3D MRA 163, 168
 cystic 168
 extent determination by MRI 161, 163, 164–168
 inferior vena cava invasion 166, 326, 326, 327

renal cell carcinoma (RCC)
kidney contour distortion 162, 165, 166–167
liver metastases 20, 21, 339
metastatic lymph nodes 163, 168, 335, 336
Robson/TNM classification 162
venous invasion 163, 166, 326
renal collecting system, dilatation 154
renal columnar hypertrophy 356
renal cysts 151, 152, 154, 155
complicated 154, 156, 157
hemorrhagic 154, 157
polycystic kidney disease 154, 155–156, 352
simple 154, 155
renal dysplasia, multicystic 352, 353
renal infarction 356
renal inflammation 151
renal lymphoma 171, 172, 173
renal oncocyroma 155, 158, 159
renal transplant 175
3D MRA evaluation after 321, 322, 323
complications 175, 176, 177
living donor evaluation 174, 174
3D MRA 320, 321, 322
MRI imaging protocol 175
normal MR angiography 322
rejection 175, 177
renal trauma 151, 152
renal tumors
benign 155, 158, 158, 159
angiomyolipoma 160, 160, 161
multilocular cystic nephroma 160
oncocytoma 155, 158, 159
rare 158, 160–161
small solid tumors 161
children/infants 353–356
malignant 161–173, 162
lymphoma 171, 172, 173
metastases 171, 172, 173
primary 161–171
rare 162, 171
transitional cell carcinoma 163, 169, 170
see also renal cell carcinoma (RCC)
renal veins
compression 326
diseases in children 356, 356, 357
left 323–324
retroaortic left 325
thrombosis 326, 356, 358
tumor-related obstruction 326, 326
renovascular hypertension 320
repetition time (RT), MR angiography 306, 307
Resovist 9, 10, 27, 28–29
respiratory triggering, bile/pancreatic duct imaging 48
respiratory motion artifacts *see* breathing motion artifacts
respiratory triggering 8, 9, 28–29
retrocaval lymph nodes 336, 339
retroperitoneal collaterals 324, 324
retroperitoneal fat 184
retroperitoneal fibrosis, idiopathic 204, 206
retroperitoneal fistula 195
retroperitoneal lymphadenopathy 326

retroperitoneal lymph nodes 335
metastases 331
normal 334
retroperitoneal soft-tissue tumors 197, 200
benign vs malignant 200, 201
characteristics (margination/growth/necrosis) 200–202
classification 197, 198–199
enhancement patterns 200
epidemiology/incidence/staging 197, 199
fibrosarcoma 203, 204
initial diagnostic work-up 200–206
invasion/spread 200, 201, 202
leiomyosarcoma 197, 202–203
lipoma 202, 202
liposarcoma 200, 201, 202
malignant fibrous histiocytoma 204, 205
mixed benign 200, 201
MRI follow-up scheme 206
patterns of spread 195
rare tumors 204, 205
recurrence, MRI 206
sarcomas 197, 200–201
T2 w and T1 w sequence intensity 201
retroperitoneal xanthofibrogranulomatosis 204, 206
retroperitoneum 195–207
advantages of MRI 195, 197, 206
children/infants, MRI imaging 195, 352
diffuse (nontumorous) diseases 204, 206
indications for MRI 195, 196
metastatic disease 206
MRI imaging technique 195–197
coils 195
contrast media 196–197, 200
imaging planes 195–196
pulse sequences 196, 196
normal anatomy 197
tumorlike lesions 197
tumors *see* retroperitoneal soft-tissue tumors
rhabdomyolysis 103–104
rhabdomyosarcoma
bladder 215, 362
prostate 237, 237, 362
renal 171
vaginal 363
rheumatoid aortitis 316
rim enhancement 30
Rokitansky–Aschoff sinuses 62
Rokitansky protuberance 292
Rosai–Dorfman syndrome 363

S

sacral flexure 128, 129
salpingitis 288
salpinx *see* uterine tubes
santorinicele 52
Santorini duct 52, 71
sarcoidosis 43, 102, 103
sarcoma
bladder 215
mesenchymal, hepatic 347
prostate 237, 237, 238
see also specific types of sarcoma

schistosoma mansoni 37
schwannoma 204, 205
secretin 49
sedation, children/infants 341–342
seminal colliculus 221, 221
seminal vesicle 219–240
agenesis 223
anatomy 221, 221
bladder cancer involvement 212, 214, 215
ectopic 223
inflammation 224–225
MRI imaging 222
prostate cancer invasion 228, 229, 230, 230
see also prostate
sensitivity encoding technique (SENSE) 143
septic puerperal ovarian vein thrombosis (SPOVT) 328
Sertoli–Leydig cell tumors 293
shading sign 292
short tau inversion recovery (STIR)
sequence
colorectal cancer 121, 122
islet cell tumors 80
liver imaging 7–8
rectal/anal canal imaging 128, 137
sickle cell anemia 103, 350
siderotic nodules (Gamma–Gandy bodies) 39, 105, 106
sigmoidovesicular fistula 123, 124
signal-to-noise ratio (SNR), coils
improving 2, 47, 127, 143, 219, 309, 341
Sinerem 8, 9, 334, 336, 339, 340
single-shot technique, liver imaging 3
situs inversus 350
slice-select gradient 307
small intestine 113–119
adenocarcinoma 113
Crohn disease 114–115, 116
diverticula 115
leiomyoma and leiosarcoma 113
lipoma 119, 119
lymphoma 113, 119, 119
MRI sequence 115, 117, 117–118
radiation enteritis 115
strictures 117
thickening of wall 114, 115, 116, 117
see also gastrointestinal tract
soft-tissue tumors 197
classification 197, 198–199
epidemiology/incidence 197, 199
retroperitoneal *see* retroperitoneal soft-tissue tumors
somatostatinoma 80, 83
spasmolysis *see* antispasmodic agents
spatial encoding, MR angiography 307
specific absorption rate (SAR) 301
spectral presaturation with inversion recovery (SPIR) 8, 9
spherical transformation, lymph nodes 336
sphingomyelin, accumulation 102
spinal canal, neuroblastoma invasion 358, 359, 359
spindle cell tumors 203
spin echo (SE) sequences
for children/infants 341
in pregnancy 301
retroperitoneum imaging 196

- spleen 87–108
 abscesses 102, 350
 angiosarcoma 100
 atrophy 103
 benign tumors 93–98, 350
 cysts 93, 93, 94–95, 350
 children 350
 epidermoid 93
 diffuse disease affecting 103,
 105–106
 ectopic 350
 focal lesions, contrast media 89,
 90
 Gaucher disease 102
 hamartoma 96
 hemangioma 93, 95, 95–96
 hemangiomatosis 95, 96
 hematoma 102
 hemorrhagic lesion 96
 indications for MRI 87
 infarction 103, 104, 350
 infectious conditions 102
 inflammatory pseudotumor 96, 98,
 99
 inhomogeneous appearance 95, 96,
 100
 iron deposition 102, 103–104, 104,
 105
 littoral cell angioma 96, 97
 lymphangioma 96
 lymphoma 90, 99, 99, 100
 malignant tumors 88, 99–100
 children 350
 metastases 100, 101, 101–102, 350
 MRI imaging technique 87–90, 89,
 89
 contrast media 87, 89–90, 91, 91,
 95
 imaging planes 87, 88, 89
 pulse sequences 87, 89, 91
 sequence protocol 90
 SPIO, signal loss after 99
 SPIO preparation use 90, 91–92,
 92
 neonatal, MRI appearance 92
 noninfectious conditions 102
 normal MRI appearance 88, 91,
 91–92
 pathologic conditions, MRI appear-
 ance 93–106
 children/infants 350
 pseudocysts 93, 102
 rupture 350
 sarcoidosis 102, 103
 sphingomyelin accumulation 102
 trauma 102, 350
 splenic artery, pseudoaneurysm 74
 splenic vein 312
 thrombosis 66, 74
 splenomegaly 103, 104, 105, 106
 splenoportal venous axis 323–324
 splenorenal shunt, spontaneous, con-
 trast-enhanced MRA 308, 324
 STEAM sequences (stimulated echo
 acquisition mode) 222
 Stein-Leventhal syndrome 289–290
 stenting
 abdominal/pelvic arteries, 3D MRA
 314, 314
 renal artery 320–321
 stomach 112–113
 adenocarcinoma 112, 112, 113, 114
 metastases 112
 staging 112
 leiomyoma, leiomyosarcoma 112
 lymphoma 112
 MRI sequences/technique 112,
 112–113, 113, 114
 signet-ring carcinoma 112, 297, 297
 see also gastrointestinal tract
 string of pearls appearance, pancreas
 73, 74
 subcutaneous fistula, Crohn disease
 138, 138
 superior mesenteric artery 305
 atherosclerotic stenosis 320
 normal MRA 312, 319
 superior mesenteric vein 312, 312
 superparamagnetic iron oxide par-
 ticles (SPIO) 27, 28, 29, 30, 30, 31
 liver imaging 8–9, 39
 splenic imaging 90, 91–92, 92, 99
 ultra-small see ultra-small super-
 paramagnetic iron oxide particles
 (USPIO)
 suprlevator abscess 138, 139, 140
 surface rendering, MRA 308, 322
 syphilitic aortitis 316
- T**
- Takayasu aortitis/arteritis 316, 319,
 350
 tampon use, vaginal MRI 241, 249
 target sign 19, 19, 117
 teratoma
 mature cystic 292–293, 293
 ovarian 361, 362
 presacral 362–363, 364
 Teslascan (Mn-DPD) 8, 9, 31, 34, 69
 testicular feminization 360
 testicular tumors 331, 361
 testicular veins 326
 testis, undescended 361
 thecomas 293, 294
 thorotrastosis 103
 time of inversion (TI) 7
 total mesorectal excision (TME) 128,
 132
 transesophageal echocardiography
 (TEE), aorta 314–315
 transitional cell carcinoma (TCC)
 bladder 211–214
 prostate 237
 renal pelvis 163, 169, 170
 transjugular intrahepatic portosyste-
 mic shunt (TIPS) 325
 translevator fistula 140
 transrectal prostate biopsy, MR-
 guided 234, 234
 transsphincteric fistula 138, 138
 transvaginal ultrasound (TVUS) 285,
 288
 trimethylsilyl propionate (TSP) 222
 TrueFISP, gastrointestinal tract
 110–111
 colorectal cancer 120, 121, 122
 functional disorders of rectum 140
 TSE sequence
 adnexa imaging 286
 for children/infants 341
 intra-abdominal lymph nodes 332,
 332, 333, 334
 liver MRI 3, 5
 pelvic MRI 242, 252
 rectum MRI 128
 retroperitoneum MRI 196
 tubal cancer/conditions see uterine
 tubes
 tuberculosis, adrenal 184–185
 tubo-ovarian abscess 288
 turbo inversion recovery sequence
 (TIR) 8
 turbo spin echo sequence see TSE se-
 quence
 tyrosine kinase inhibitor (imatinib)
 113–114, 197
- U**
- ulcer, penetrating atherosclerotic 314
 ulcerative colitis 121, 123, 123, 124
 children 343, 345
 Crohn disease vs 123
 ultra-small superparamagnetic iron
 oxide particles (USPIO) 9, 307, 334
 endometrial carcinoma staging
 266
 malignant lymph nodes 331, 332,
 334, 336, 340
 normal lymph nodes 339
 optimal imaging time point 334
 retroperitoneum imaging 196
 ultrasound
 in children/infants 342
 pelvic 241, 266–267
 prostate cancer 235
 transvaginal 285, 288
 ureter 246
 dilatation and obstruction 154
 ectopic insertion 150, 151
 stones 154, 154
 see also kidney; urinary tract, upper
 urethra 221
 carcinoma 212, 215
 diverticula 210, 211
 urinary bladder see bladder (urinary)
 urinary incontinence 150
 urinary obstruction 154
 urinary tract, upper 143–179
 MRI imaging technique see under
 kidney
 obstruction 154
 see also ureter
 urinoma 175, 175, 357
 urothelial carcinoma see transitional
 cell carcinoma (TCC)
 uterine arteries 259, 287
 uterine artery embolization (UAE) 255
 uterine tubes
 blockage 288
 cancer 297
 dilated 290, 291
 functioning tumors 293, 294
 imaging technique 285–286
 indications for MRI 285
 MR hysterosalpingography 288,
 289
 MRI imaging technique 285–286
 normal anatomy/MRI 287
 uterosacral ligament 246, 246
 uterovesical ligament 246, 246
 uterus 241–283
 acquired benign disorders 255–262
 adenomyosis 258, 260, 260–261,
 262

uterus
 agenesis (complete/partial) 253,
 253
 arcuate 255
 atrophy 277
 benign vs malignant tumors 256
 bicornuate 252, 254, 254–255, 360
 congenital anomalies 252, 252–255
 pulse sequences 253, 253
 corpus 245, 245
 dilatation and curettage, MRI after
 276
 double 252, 253, 254, 255, 360
 dynamic contrast-enhanced 244,
 257, 259
 gestational trophoblastic disease
 261
 hormone treatment affecting 248,
 249
 hypoplasia 253
 indications for MRI 241, 252
 isthmus 245, 245
 junctional zone 247
 focal 260, 260–261
 thickened, adenomyosis 260, 260
 leiomyoma (fibroids) 255–257, 263,
 279
 adenomyosis with 258, 260
 degenerative changes 258, 257
 intramural 255, 256, 256
 MRI appearance 256, 256–257,
 257
 ovarian fibroma vs 293
 pedunculated 256, 257, 258, 293
 pseudocapsule 256, 257, 260
 pulse sequences 256, 256
 submucosal 255, 256
 subserosal 255, 256, 257, 258
 ligaments supporting 246, 246
 malignant tumor see endometrial
 carcinoma
 before menarche 247, 248
 menstrual cycle effects 247, 247,
 248
 MRI imaging technique see pelvic
 MRI
 MRI vs CT/ultrasound 241, 266–267
 neonatal 247
 normal MRI appearance 245,
 245–249, 246, 247
 peritoneum covering 246, 246
 postmenopausal women 248, 249

radiotherapy, MRI appearance after
 276–277, 277
 residual tumor after 278, 280
 rudimentary horn 254, 254
 septate 252, 255, 255
 T1 w sequences 244, 246–247, 247,
 253
 T2 w sequences 244, 248, 249, 253
 unicornuate 252, 254, 254
 zonal anatomy 246–247, 247, 248
 uterus didelphys 252, 253, 254, 360

V

vagina 241–283
 agenesis 254, 274
 atresia 360
 cervical cancer invasion 271, 272,
 273, 275
 congenital anomalies 274
 cysts 274
 double 254, 274, 274, 360
 endometrial carcinoma invasion
 262
 indications for MRI 241
 menstrual cycle effect 249
 MRI imaging technique see pelvic
 MRI
 normal anatomy 245
 normal MRI appearance 249, 251
 pathologic entities, MRI 274–276
 postmenopausal women 249
 radiotherapy effect 277, 277–278
 stenosis, radiation-induced 277,
 277, 278, 278
 T1 w images 249, 251
 T2 w sequence (axial) 244, 249
 tumors 274–276
 pulse sequences/protocol
 275–276, 276
 rhabdomyosarcoma 363
 staging 275, 275–276, 276
 wall, carcinoma involvement 271,
 276
 vaginal bleeding 267
 vaginal fornix, normal MRI 249, 250
 vaginal septum 253–254
 vaginal stump 278, 280
 vaginal vault, ovarian cancer 298, 298
 vascular malposition 350, 351
 Vasovist (gadofosveset) 307

vena cava
 displacement 353, 355
 thrombosis 358
see also inferior vena cava
 vena cava compression syndrome 303
 VIBE sequence (volume-interpolated
 breath-hold examination)
 adrenal gland MRI 182, 182
 gastrointestinal tract 109, 110,
 111–112, 115
 colorectal cancer 120, 121, 122
 inflammatory disease of colon
 124
 kidney and upper urinary tract 144,
 146
 liver MRI 3
 pancreas MRI 66
 retroperitoneum MRI 196
see also GRE sequences, 3D
 VIPoma 80
 visceral arteries
 aneurysm 319
 mesenteric ischemia 319, 319, 320
 MR angiography 318–319, 319

W

Wilms tumor (nephroblastoma) 171,
 171, 353–355, 354–355
 benign variant 160
 differential diagnosis 355, 358
 extrarenal 353
 monitoring, MRI 353, 354–355
 subtypes and staging (SIOP) 353,
 353

Wilson disease 42–43, 347

X

xanthofibrogranulomatosis, retroperi-
 toneal 204, 206

Y

yolk sac tumors 361

Z

Zollinger–Ellison syndrome 80